^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

KAND757

i
Other names: KAND757, KAN0438757
Associations
Trials
Company:
Kancera
Drug class:
PFKFB3 inhibitor
Associations
Trials
11d
Deciphering the Anti-Cancer Efficacy of the Combination of Small-Molecule Inhibitor KAN0438757 and Curcumin in Lung Cancer Cell Lines. (PubMed, Curr Issues Mol Biol)
The comet assay revealed severe DNA damage (Tail DNA, fold change, untreated cell; 1, CUR-20 µM; 1.2, KAN-20 µM; 3, and COMB; 4.6) in the A549 cells, while MMP analysis (color change from red to green) and apoptotic staining confirmed cell death morphologically (color change from green to orange). Moreover, Western blot analysis demonstrated that the combination markedly enhanced apoptosis in the A549 cells.
Preclinical • Journal
|
PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3)
|
KAND757
almost2years
PFKFB3 facilitates cell proliferation and migration in anaplastic thyroid carcinoma via the WNT/β-catenin signaling pathway. (PubMed, Endocrine)
PFKFB3 can enhance ATC cell proliferation and migration via the WNT/β-catenin signaling pathway and plays a crucial role in the regulation of aerobic glycolysis in ATC cells.
Journal
|
CCND1 (Cyclin D1) • MMP9 (Matrix metallopeptidase 9) • NECTIN1 (Nectin Cell Adhesion Molecule 1) • PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3)
|
MK-2206 • KAND757
3years
In vitro and in vivo characterization of the novel PFKFB3 inhibitor KAN0438757 in colorectal cancer (DKK 2022)
KAN0438757 showed a clear antiproliferative effect in rectal cancer cells and PDX without being overly toxic in vivo. It showed promis- ing synergistic efficacy when used in combination with chemotherapy and therefore should be further tested in vivo.
Preclinical
|
PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit) • PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3)
|
KAND757